EU/3/18/2115

About

On 14 December 2018, orphan designation (EU/3/18/2115) was granted by the European Commission to Yes Pharmaceutical Development Services GmbH, Germany, for human anti-promyostatin monoclonal antibody (also known as SRK-015) for the treatment of spinal muscular atrophy.

Key facts

Active substance
Human anti-promyostatin monoclonal antibody
Disease / condition
Treatment of spinal muscular atrophy
Date of decision
14/12/2018
Outcome
Positive
Orphan decision number
EU/3/18/2115

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Yes Pharmaceutical Development Services GmbH
Bahnstraβe 42-46
61381 Friedrichsdorf
Germany
Tel. +4961727646465
E-mail: martyn.critchley@pharmalex.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating